nevirapine has been researched along with Mental Disorders in 5 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study." | 1.33 | Are adverse events of nevirapine and efavirenz related to plasma concentrations? ( Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F, 2005) |
| " This is a retrospective analysis of virologic efficacy and changes in adverse neuropsychiatric effects and serum lipid levels after this switch." | 1.33 | Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. ( Curtin, JM; Ward, DJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pedrol, E | 1 |
| Llibre, JM | 1 |
| Tasias, M | 1 |
| Currán, A | 1 |
| Guardiola, JM | 1 |
| Deig, E | 1 |
| Guelar, A | 1 |
| Martínez-Madrid, O | 1 |
| Tikhomirova, L | 1 |
| Ramírez, R | 1 |
| Kappelhoff, BS | 1 |
| van Leth, F | 1 |
| Robinson, PA | 1 |
| MacGregor, TR | 1 |
| Baraldi, E | 1 |
| Montella, F | 1 |
| Uip, DE | 1 |
| Thompson, MA | 1 |
| Russell, DB | 1 |
| Lange, JM | 1 |
| Beijnen, JH | 1 |
| Huitema, AD | 1 |
| Ward, DJ | 1 |
| Curtin, JM | 1 |
| Arendt, G | 1 |
| de Nocker, D | 1 |
| von Giesen, HJ | 1 |
| Nolting, T | 1 |
| Gonzalez, A | 1 |
| Everall, IP | 1 |
1 review available for nevirapine and Mental Disorders
| Article | Year |
|---|---|
Neuropsychiatric side effects of efavirenz therapy.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Humans; Mental Disorders; Neuropsychological Tests; Nevirapine | 2007 |
4 other studies available for nevirapine and Mental Disorders
| Article | Year |
|---|---|
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Di | 2015 |
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug In | 2005 |
Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Lipids; | 2006 |
Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
Topics: Anti-HIV Agents; Antipsychotic Agents; Blood-Brain Barrier; Central Nervous System; Cytochrome P-450 | 1998 |